| Summary: | The purpose of this rapid review is to determine if COVID treatments authorized for emergency use by the Food and Drug Administration (FDA) are associated with serious harms. The review will be used by the Health Resources & Services Administration (HRSA) Countermeasures Injury Compensation Program to inform a Countermeasures Injury Table (Table). Once a Table and any relevant amendments are published, the Table will be used to make benefits eligibility determinations for covered injuries or deaths. The Agency for Healthcare Research and Quality (AHRQ) commissioned this rapid review using abbreviated methods to provide an assessment of evidence in a compressed timeframe to inform HRSA's work. The following pharmaceutical interventions to treat or prevent COVID-19 were reviewed: Convalescent plasma (from recovered COVID-19 patients); Antivirals: Remdesivir (Veklury), Nirmatrelvir and Ritonavir in combination (Paxlovid), Molnupiravir (Lagevrio); Monoclonal antibodies: Bamlanivimab and Etesevimab in combination, Bebtelovimab, Casirivimab and Imdevimab in combination (Regeneron), Sotrovimab (Xevudy), Tixagevimab and Cilgavimab in combination (Evusheld), Tocilizumab (Actemra); Interleukin-1 receptor antagonist: Anakinra (Kineret)
|
|---|